---
schema_version: "secwatch.filing_event.v1"
accession: "0001567264-26-000061"
form_type: "8-K"
ticker: "INTS"
cik: "0001567264"
company_name: "INTENSITY THERAPEUTICS, INC."
filed_at: "2026-08-11T11:40:55+00:00"
generated_at: "2026-08-11T11:45:11.072009+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Intensity Q2 2026 net loss $3.0M; resumes sarcoma and TNBC trials

## Summary
- Q2 2026 net loss $3.0M vs $2.5M in Q2 2025; R&D $1.8M, G&A $1.3M.
- Cash $9.5M at June 30; raised $1.6M net from ATM in Q2, $1.3M more after quarter end.
- Phase 3 INVINCIBLE-3 resumed enrollment activities in April 2026 after FDA-reviewed protocol amendment; 21 patients previously enrolled.
- Phase 2 INVINCIBLE-4 restarted treatment in July 2026; preliminary pCR 71% vs 42% for SOC; full enrollment targeted by end 2027.
- Opened first France site for INVINCIBLE-4; increased business development activities.

## SEC filing metadata
- accession: 0001567264-26-000061
- form_type: 8-K
- ticker: INTS
- cik: 0001567264
- company_name: INTENSITY THERAPEUTICS, INC.
- filed_at: 2026-08-11T11:40:55+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1567264/000156726426000061/0001567264-26-000061-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1567264/000156726426000061/intensity-20260811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001567264-26-000061
- JSON: https://secwatch.observer/filing/0001567264-26-000061.json
- Plain text: https://secwatch.observer/filing/0001567264-26-000061.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.